Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study ; volume:22 ; number:1 ; day:11 ; month:1 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cancer ; 22, Heft 1 (11.1.2022), 1-8, 12.2022

Creator: Chen, San-Chi
Huang, Yi-Hsiang
Chen, Ming-Huang
Hung, Yi-Ping
Lee, Rheun-Chuan
Shao, Yu-Yun
Chao, Yee

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-022-09173-4

URN: urn:nbn:de:101:1-2022042521383500820086

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Chen, San-Chi
Huang, Yi-Hsiang
Chen, Ming-Huang
Hung, Yi-Ping
Lee, Rheun-Chuan
Shao, Yu-Yun
Chao, Yee
SpringerLink (Online service)

Other Objects (12)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Management of Localized Melanoma in the Anti-PD-1 Era

Hochschulschrift

Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Hochschulschrift

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie

Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Management of Localized Melanoma in the Anti-PD-1 Era

Hochschulschrift

Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Hochschulschrift

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie

Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Management of Localized Melanoma in the Anti-PD-1 Era

Hochschulschrift

Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Hochschulschrift

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie

Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Management of Localized Melanoma in the Anti-PD-1 Era

Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie

Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Management of Localized Melanoma in the Anti-PD-1 Era

Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie

Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Management of Localized Melanoma in the Anti-PD-1 Era

Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie

Strategies for sensitizing tumors to Anti-PD-1 immune checkpoint blockade

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?

Related objects

Reset password